表紙
市場調査レポート

腎細胞癌:世界の治験動向

Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 230796
出版日 ページ情報 英文 1153 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
腎細胞癌:世界の治験動向 Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
出版日: 2016年07月29日 ページ情報: 英文 1153 Pages
概要

当レポートでは、腎細胞癌治療薬に関する治験の最新動向について分析しており、G7 (主要7カ国) 諸国およびE7 (新興7カ国) における治験件数、被験者数、有望なスポンサー、治験に携わっている主な企業や機関、有望な薬剤の情報をまとめています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:癌治療薬の治験における腎細胞癌の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:癌治療薬の治験における腎細胞癌の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

腎細胞癌治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験プロファイルの概要

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3633CTIDB

GlobalData's clinical trial report, "Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016" provides an overview of Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Renal Cell Carcinoma Therapeutics Clinical Trials 28
  • Prominent Drugs 29
  • Latest Clinical Trials News on Renal Cell Carcinoma 30
  • Aug 04, 2016: Gene expression profile may ID renal cell carcinoma pts unlikely to benefit from nivolumab 30
  • Jul 08, 2016: Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma 30
  • Jun 06, 2016: Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity 31
  • Jun 06, 2016: Calithera Biosciences Reports CB-839 Phase I Solid Tumor Combination Data at the American Society of Clinical Oncology Annual Meeting 32
  • Jun 05, 2016: Long-Term Survival and Improvement in Quality of Life Observed with Opdivo (nivolumab) in Advanced Renal Cell Carcinoma Patients Based on New Data Presented at the 2016 ASCO Annual Meeting 33
  • Jun 05, 2016: Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO 34
  • Jun 05, 2016: Tyrogenex Presents Data Informing Phase II and Supporting Potential Efficacy of X-82 with Everolimus in Patients with Solid Tumors at the ASCO Annual Meeting 2016 35
  • Jun 05, 2016: BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting 36
  • May 26, 2016: AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma 37
  • May 23, 2016: Ipsen's partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma 37
  • May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma 38
  • Clinical Trial Profile Snapshots 41

Appendix 1150

  • Abbreviations 1150
  • Definitions 1150
  • Research Methodology 1151
  • Secondary Research 1151
  • About GlobalData 1152
  • Contact Us 1152
  • Disclaimer 1152
  • Source 1153

List of Tables

List of Tables

  • Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region, 2016* 7
  • Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
  • Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
  • Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14
  • Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2016* 15
  • Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
  • Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
  • Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2016* 18
  • Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
  • Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
  • Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2016* 21
  • Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
  • Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
  • Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures

List of Figures

  • Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 7
  • Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
  • Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
  • Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14
  • Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2016* 15
  • Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
  • Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
  • Proportion of Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2016* 18
  • Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
  • Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
  • Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
  • Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
  • Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
  • Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
  • Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
  • GlobalData Methodology 1151
Back to Top